Glenmark, Merck win reversal of class certification in Zetia pay-for-delay case
MLex Summary: Glenmark and Merck have gotten class certification reversed in direct purchasers’ antitrust case alleging an illegal pay-for-delay agreement over the cholesterol drug Zetia. The US Court of Appeals for the...To view the full article, register now.
Already a subscriber? Click here to view full article